LPCN
Lipocine Inc.
There isn't enough reported data to score LPCN yet.
LPCN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Unavailable | |
| Unavailable |
LPCN's revenue is currently stable, but its profitability is weak. There isn't enough data to rate its cash flow and balance sheet.
LPCN PE Valuation
LPCN has no meaningful PE right now: it lost money over the past year.
LPCN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect LPCN's losses to shrink, with revenue declining.
LPCN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.28 | -$0.27 |
| Q2 2026 | -$1.79 | -$0.93 |
| Q1 2026 | -$1.88 | -$0.87 |
| Q4 2025 | -$1.69 | -$1.69 |
| Q3 2025 | -$1.01 | +$0.48 |
| Q2 2025 | -$0.86 | +$1.45 |
| Q1 2025 | -$1.01 | +$1.42 |
| Q4 2024 | -$0.00 | +$3.77 |
LPCN is still losing money, but far less than before: $1.28 per share over the past year, against $8.50 at its worst in late 2019.
LPCN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.3M | +1899% |
| Q2 2026 | $190.1K | -69% |
| Q1 2026 | $119.4K | +27% |
| Q4 2025 | $1.1M | -67% |
| Q2 2025 | $622.8K | +595% |
| Q1 2025 | $93.9K | -99% |
| Q4 2024 | $3.5M | +1515% |
| Q1 2024 | $7.6M | +13752% |
LPCN's revenue is recovering but still below its 2021 peak: $2M last quarter, up 1899% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -38% | +2896 points |
| Q2 2026 | -1495% | -1109 points |
| Q1 2026 | -3224% | -997 points |
| Q4 2025 | -220% | -264 points |
| Q3 2025 | -2934% | N/A |
| Q2 2025 | -386% | +3290 points |
| Q1 2025 | -2227% | -2269 points |
| Q4 2024 | 44% | +1244 points |
LPCN's operating margin was −38% last quarter, up 2896 points from the same quarter a year ago.
LPCN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3M | -$1.1M |
| Q1 2026 | -$2.3M | -$287.9K |
| Q4 2024 | $1.7M | +$3.7M |
| Q4 2023 | -$2M | -$95.8K |
| Q3 2023 | -$2.6M | +$592.1K |
| Q2 2023 | -$3.3M | -$253K |
| Q1 2023 | -$3.9M | -$19.9K |
| Q3 2022 | -$3.2M | +$3.8M |
LPCN has burned cash in almost every quarter: −$9M over the past year, against −$5M the year before.
LPCN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +27.6K shares |
| 1 year | +54% | +2.9M shares |
| 3 years | +57% | +3M shares |
| 5 years | +59% | +3.1M shares |
| Available history | +239% | +5.8M shares |
LPCN has 8M diluted shares, up 54% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2023 | — |
LPCN Net Leverage
LPCN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LPCN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.9 | Neutral |
| Stochastic | 9.5 | Oversold |
LPCN's weekly RSI is 35 (neutral) and its Stochastic is 10 (oversold).
LPCN PE vs Healthcare Sector
| Metric | LPCN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
LPCN has no meaningful PE right now: it lost money over the past year.
LPCN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.69 | 4.1% below |
| 20 week MA | $2.01 | 19% below |
| 50 week MA | $3.99 | 59% below |
| 100 week MA | $3.69 | 56% below |
| 200 week MA | $4.28 | 62% below |
LPCN is in a downtrend: it's below all five of its weekly moving averages, and 62% below its 200-week average.
LPCN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.04 | $24.1 | +300% |
| 2021 | $24.1 | $18.0 | -25% |
| 2022 | $18.0 | $6.90 | -62% |
| 2023 | $6.90 | $2.79 | -60% |
| 2024 | $2.79 | $4.76 | +71% |
| 2025 | $4.76 | $5.23 | +9.9% |
| 2026 YTD | $5.23 | $1.62 | -69% |
LPCN's yearly returns have swung widely, from +300% in 2020 to −62% in 2022. It's down 69% so far in 2026.